Engineers Gate Manager’s Cymabay Therapeutics CBAY Stock Holding History

Engineers Gate Manager’s Portfolio CBAY Stock Details CBAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-53,982	Closed	-$805K	–	2337
2023 Q3	$805K	Buy	+53,982	New	+$716K	0.03%	823
2021 Q3	–	Sell	-10,989	Closed	-$48K	–	2061
2021 Q2	$48K	Buy	10,989 +296	+3%	+$1.31K	﹤0.01%	1547
2021 Q1	$49K	Buy	+10,693	New	+$57.5K	﹤0.01%	1747
2020 Q3	–	Sell	-59,912	Closed	-$209K	–	2047
2020 Q2	$209K	Buy	59,912 +42,239	+239%	+$122K	0.01%	1428
2020 Q1	$26K	Sell	17,673 -69,887	-80%	-$117K	﹤0.01%	1511
2019 Q4	$172K	Buy	87,560 +48,067	+122%	+$181K	0.01%	1496
2019 Q3	$202K	Sell	39,493 -172,647	-81%	-$1.05M	0.01%	1201
2019 Q2	$1.52M	Buy	212,140 +120,487	+131%	+$1.36M	0.08%	385
2019 Q1	$1.22M	Buy	91,653 +31,714	+53%	+$337K	0.07%	389
2018 Q4	$472K	Buy	+59,939	New	+$571K	0.04%	541

Other funds holding CBAY

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Engineers Gate Manager's CBAY Position: Q4 2023 in Review

Engineers Gate Manager sold out of Cymabay Therapeutics (CBAY) in Q4 2023, closing a stake of 53,982 shares — an estimated $805K sold.

Engineers Gate Manager first reported a position in CBAY in Q4 2018 and held it in 10 quarters. The position peaked at $1.52M in Q2 2019. 200 funds tracked by Wall St. Rank hold CBAY as of Q4 2023.

Engineers Gate Manager reported no remaining Cymabay Therapeutics position as of Q4 2023 after selling out during the quarter.
Engineers Gate Manager sold 53,982 Cymabay Therapeutics shares in Q4 2023, an estimated $805K.
Engineers Gate Manager first reported a position in Cymabay Therapeutics in Q4 2018 and held it in 10 quarters.
Engineers Gate Manager's Cymabay Therapeutics position peaked at $1.52M in Q2 2019.
200 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q4 2023.

Based on Engineers Gate Manager's 13F filing for Q4 2023, filed 14 Feb 2024.